Prescription medicine
Doxecitine and doxribtimine Brand names: Kygevvi
Doxecitine and doxribtimine (Kygevvi) is a prescription medicine with an FDA approval on record since 2025. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the doxecitine and doxribtimine FDA label on DailyMed (effective November 10, 2025, UCB, Inc.); the NDA 219792 record on Drugs@FDA; every doxecitine and doxribtimine label on DailyMed.
Highlights of the record
FDA label of November 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageKYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
Forms and strengths
- 2 g / 2 g
Powder for solution.
On the market
- Earliest approval on file
- November 3, 2025 Kygevvi, Ucb Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- August 19, 2040 Kygevvi for solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 8 through July 30, 2026
What is doxecitine and doxribtimine used for?
From the label: indications and usageKYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
Source: FDA drug label (KYGEVVI), NDA219792 (Ucb Inc), as published by UCB, Inc., effective November 10, 2025 (SPL set 7d5ce670-9314-4fd7-8b0a-1447910dcf9e), via openFDA; the full label on DailyMed
Is there a generic for doxecitine and doxribtimine (Kygevvi)?
No generic doxecitine and doxribtimine is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Kygevvi for solution, the last expiring on August 19, 2040. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2025 earliest approval on file
- 2040 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for doxecitine and doxribtimine?
The FDA Adverse Event Reporting System holds 8 reports that list doxecitine and doxribtimine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Doxecitine and doxribtimine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other